Tirzepatide

Lipedema is a chronic, progressive adipose tissue disorder that affects up to 10% of women and is characterized by disproportionate lower-limb fat accumulation, pain, edema, and resistance to conventional weight-loss approaches. Its pathophysiology i…

This report describes the first case of maturity-onset diabetes in young (MODY) with HNF1B mutation started administration of the dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, tirzepatide. A 26-year-o…

BACKGROUND: Glucagon-like peptide-1 (GLP-1) analogs are approved for the treatment of obesity in adults and adolescents. Reports have emerged that the weight loss effect of these medications may be related to changes in food preferences and ingestive…

Tirzepatide, a dual GIP/GLP-1 receptor agonist, has shown unprecedented efficacy in weight loss and improving metabolic parameters in clinical trials. However, the durability of these benefits after treatment cessation remains poorly understood. This…

OBJECTIVES: This study evaluates the cost-effectiveness of tirzepatide (TZP) 10 and 15 mg once weekly (QW) compared to placebo among individuals with type 2 diabetes (T2D) and comorbid obesity in the United States (US). RESEARCH DESIGN AND METHODS: T…

INTRODUCTION: Currently, limited guideline-directed medical therapies are available for heart failure (HF) with preserved and mildly reduced ejection fraction (EF). Both are associated with an increased risk of hospitalization and death, especially i…

Glucagon-like peptide-1 receptor agonist (GLP-1RA) has attracted attention owing to its hypoglycemic and weight-loss effects, and various dosage forms are available in the market. Recently, glucose-dependent insulin secretion-stimulating polypeptide…

BACKGROUND: OSA is a prevalent chronic condition linked to obesity that is associated with increased risks of cardiovascular and kidney disease. Although weight loss can improve OSA outcomes, additional effective therapeutic options are needed. Tirze…

The management of type 2 diabetes has evolved significantly with the advent of incretin-based therapies, particularly dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists. In Japan, where over 70% of individuals with diabet…

AIMS/INTRODUCTION: In the SURPASS J-mono trial, tirzepatide demonstrated significant improvements in bodyweight and several metabolic parameters in Japanese participants with type 2 diabetes. This post hoc analysis evaluated the potential relationshi…

Doxorubicin (DXN) is widely utilized for the treatment of various cancer types. However, prolonged DXN administration induces vascular impairment and neurological effects, including cognitive deficits. Here, we investigated the efficacy of tirzepatid…

RATIONALE: Managing type 2 diabetes mellitus (T2DM) in adults with severe obesity frequently coexists with obstructive sleep apnea (OSA), complicating metabolic control and quality of life. Real-world, objective monitoring-documented trajectories thr…

Glucagon-like peptide-1 (GLP-1) receptor agonists and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) agonists, such as tirzepatide, have transformed the management of type 2 diabetes and obesity through durable glycemic control, weight…

BACKGROUND: Acute pancreatitis (AP) is a severe inflammation of the pancreas, marked by elevated enzyme levels, cellular inflammation, and necrosis. Recent studies emphasize the critical role of inflammation in AP progression. Tirzepatide, a multi-ta…

PURPOSE: In this study, we aim to explore the effects of tirzepatide on the gut microbiota in mice with obesity induced by a high-fat diet. METHODS: Forty male C57BL/6J mice, aged six weeks, were randomly assigned to one of four experimental groups:…

BACKGROUND: With the increasing clinical use of tirzepatide, its safety profile has garnered significant attention. This article systematically reviews case reports of tirzepatide-associated adverse drug reactions (ADRs) to summarize their characteri…